What is Northland Capmk's Estimate for HRTX Q2 Earnings?

Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) - Stock analysts at Northland Capmk issued their Q2 2025 earnings estimates for Heron Therapeutics in a research note issued on Tuesday, May 6th. Northland Capmk analyst C. Byrnes forecasts that the biotechnology company will earn ($0.01) per share for the quarter. The consensus estimate for Heron Therapeutics' current full-year earnings is ($0.13) per share. Northland Capmk also issued estimates for Heron Therapeutics' FY2025 earnings at $0.01 EPS.

Heron Therapeutics (NASDAQ:HRTX - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The biotechnology company reported $0.01 EPS for the quarter, beating analysts' consensus estimates of ($0.01) by $0.02. The company had revenue of $38.90 million during the quarter, compared to analyst estimates of $37.08 million.

Several other research firms have also weighed in on HRTX. Needham & Company LLC reaffirmed a "buy" rating and issued a $4.00 price objective on shares of Heron Therapeutics in a research note on Friday, April 11th. StockNews.com lowered shares of Heron Therapeutics from a "buy" rating to a "hold" rating in a report on Saturday, March 8th.

Heron Therapeutics Trading Down 8.8%

NASDAQ HRTX traded down $0.18 on Thursday, hitting $1.87. 1,937,115 shares of the company's stock were exchanged, compared to its average volume of 2,320,825. Heron Therapeutics has a 52 week low of $1.04 and a 52 week high of $3.93. The stock has a 50-day moving average of $2.18 and a 200-day moving average of $1.82. The stock has a market cap of $285.29 million, a price-to-earnings ratio of -10.39 and a beta of 1.33.

Hedge Funds Weigh In On Heron Therapeutics

Several large investors have recently bought and sold shares of HRTX. Anfield Capital Management LLC increased its stake in shares of Heron Therapeutics by 18.7% in the first quarter. Anfield Capital Management LLC now owns 141,185 shares of the biotechnology company's stock valued at $311,000 after buying an additional 22,209 shares during the period. Informed Momentum Co LLC acquired a new position in Heron Therapeutics in the 1st quarter valued at approximately $768,000. Capital Planning Advisors LLC increased its position in Heron Therapeutics by 29.6% in the 1st quarter. Capital Planning Advisors LLC now owns 138,095 shares of the biotechnology company's stock valued at $304,000 after acquiring an additional 31,530 shares during the period. Nuveen LLC bought a new position in shares of Heron Therapeutics during the first quarter valued at $691,000. Finally, Invesco Ltd. lifted its holdings in shares of Heron Therapeutics by 67.6% during the first quarter. Invesco Ltd. now owns 119,662 shares of the biotechnology company's stock worth $263,000 after purchasing an additional 48,263 shares during the period. 80.01% of the stock is currently owned by institutional investors.

About Heron Therapeutics

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.